Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • bswhite
    Junior Member
    • Jan 2014
    • 5

    gene-level effects in DEXSeq

    Hi,

    I've just updated to DEXSeq 1.10.8. The manual claims that DEXSeq
    fits a GLM for each gene (section 3.4 Testing for differential exon
    usage), which I would expect. However, the formulae presented in that
    section do not include any gene-level effects:

    e.g., full model ~ sample + exon + condition:exon

    In previous versions of DEXSeq incorporating the gene effect would
    have been accomplished by selecting out the (exon) count rows
    corresponding to a gene and performing the test individual on those
    rows. i.e., with testGeneForDEU. But I don't see any similar partitioning
    of the data by gene in DEXSeq 1.10.8. Can someone verify that it
    is indeed fitting the GLM on a per-gene basis and how it is doing so?
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    It'll fit whatever design you give it with a GLM. You typically don't need to explicitly add "condition" since it's a linear sum of "sample", which would normally make the resulting model matrix rank insufficient.

    Comment

    • bswhite
      Junior Member
      • Jan 2014
      • 5

      #3
      Thanks. But I wasn't understanding how the gene level effect was accounted
      for given that I thought each row of the _original_ matrix of exon counts
      was processed independently. That last assumption was incorrect
      and lead to my confusion.

      Previous versions of DEXSeq aggregated rows sharing a gene in testForDEU. In this version that aggregation into "this" and "other" exons happens in DEXSeqDataSet. So that each row of the augmented matrix has the
      original counts for the exon and the summed counts for all other exons.

      This is started pretty clearly in the manual, I just missed it (e.g., section 3.1 Loading and inspecting the sample data). Hence, the gene level effect is
      absorbed into the 'sample' term (as stated in Section 3.4 Testing for differential expression).

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      26 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      38 views
      0 reactions
      Last Post SEQadmin2  
      Working...